You've probably heard the buzz. A new weight loss drug is making headlines, drawing comparisons to bariatric surgery and leaving single and duel agonist GLP-1's in the rearview mirror. But if weight loss is all you know about Retatrutide, you're only seeing a fraction of the picture. First, Let's Talk About the Weight Loss Numbers Because They're Jaw-Dropping Retatrutide isn't just another GLP-1 drug. It's triple receptor agonist - simultaneously targeting the GLP-1, GIP, an